Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sema4

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
From Sema4
Via GlobeNewswire
Tickers SMFR SMFRW
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
From Sema4
Via Business Wire
Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer
From Sema4
Via Business Wire
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
From Sema4
Via Business Wire
AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program to Optimize Patient Care and Outcomes
From Sema4
Via Business Wire
Sema4 to Participate in Upcoming Investor Conferences
From Sema4
Via Business Wire
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
From Sema4
Via Business Wire
NorthShore and Sema4 Launch System-Wide Genomics Program to Improve Primary and Specialty Care with Data-Driven Insights
From Sema4
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.